Esophageal varices are dilated submucosal veins in the esophagus resulting from portal hypertension, most commonly due to liver cirrhosis. They are present in approximately 30% of patients at the time of cirrhosis diagnosis and up to 90% of those with severely decompensated disease. [1-2] Variceal hemorrhage carries a 6-week mortality of 10–15% even with modern therapy and constitutes a true medical emergency. [3]
The following management algorithm outlines the approach to acute variceal bleeding in cirrhotic patients:
1. History
- Hematemesis (bright red blood vs. coffee-ground emesis) — red blood emesis strongly predicts variceal source (OR 4.6) [5]
- Melena or hematochezia; volume and frequency of bleeding episodes
- Known history of cirrhosis, hepatitis B/C, alcohol use disorder, or prior variceal bleeding
- Prior endoscopy findings (variceal size, red wale marks)
- Medication use: NSAIDs, anticoagulants, beta-blockers (compliance), alcohol
- Symptoms of decompensation: increasing abdominal girth (ascites), confusion (encephalopathy), jaundice
- Timing of last meal (relevant for airway management at endoscopy)
- Syncope, presyncope, lightheadedness suggesting hemodynamic compromise
2. Alarm Features
- Massive hematemesis with bright red blood — suggests active, high-volume hemorrhage [6]
- Hemodynamic instability: tachycardia, hypotension, altered mental status
- Signs of hemorrhagic shock: cool extremities, delayed capillary refill, oliguria
- Altered consciousness raising aspiration risk — requires early intubation [3][7]
- Known Child-Pugh C cirrhosis — highest mortality from variceal bleeding [3]
- Concurrent hepatic encephalopathy or hepatorenal syndrome — independent predictors of 42-day mortality [8]
- Refractory bleeding despite initial endoscopic and pharmacologic therapy
3. Medications
Acute treatment
- Octreotide: 50 mcg IV bolus → 25–50 mcg/hr infusion for 2–5 days (only vasoconstrictor available in the US for this indication) [3][7][9]
- Terlipressin: 2 mg IV q4–6h for 24–48h, then 1 mg q4–6h (not approved in North America) [3]
- Prophylactic antibiotics: IV ceftriaxone 1 g q24h (preferred over quinolones due to resistance) for up to 5 days or until discharge — reduces short-term mortality (18.5% vs 22.2%) [3][10]
- IV erythromycin 125–250 mg given 30–120 min before endoscopy to improve gastric visualization [3]
Primary/secondary prophylaxis
- Carvedilol 6.25 mg daily, titrated to 12.5 mg daily (preferred per Baveno VII) — lower bleeding rates than band ligation alone (10% vs 23%) [10]
- Propranolol 20–40 mg BID or nadolol 40 mg daily as alternatives [11]
Medications to avoid/use with caution
- NSAIDs — increase bleeding risk and worsen renal function in cirrhosis
- Aggressive crystalloid/blood product resuscitation — can worsen portal pressure [3][7]
- Liberal FFP transfusion — INR does not predict hemostatic dysfunction in cirrhosis; liberal transfusion worsens portal pressure and survival [3]
4. Diet
- NPO during acute bleeding until hemostasis confirmed and airway secure
- Early feeding within 72 hours post-endoscopy is recommended [12]
- Sodium restriction (<2 g/day) for patients with ascites, though must be balanced against caloric/protein goals [10]
- Alcohol cessation is critical — accelerates variceal development and progression [7]
- Adequate protein intake (1.2–1.5 g/kg/day) to prevent sarcopenia, with adjustment for encephalopathy
5. Review of Systems
- GI: hematemesis, melena, hematochezia, abdominal distension, early satiety, dysphagia
- Neuro: confusion, sleep-wake reversal, asterixis (hepatic encephalopathy)
- Renal: urine output, dark urine, peripheral edema
- Pulmonary: dyspnea (hepatopulmonary syndrome, aspiration), cough with blood (distinguish hemoptysis from hematemesis) [6]
- Constitutional: weight changes, fatigue, fever (infection as precipitant)
- Skin: jaundice, pruritus, easy bruising, spider angiomata
6. Collateral History and Family History
- Confirm alcohol use history (quantity, duration, last drink) — collateral from family is essential
- Medication compliance with beta-blockers or lactulose
- Prior hospitalizations for GI bleeding, paracentesis, or encephalopathy
- Family history of liver disease (hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency)
- Social context: IV drug use (hepatitis risk), housing stability, access to follow-up
7. Risk Factors
- Liver cirrhosis (any etiology) — the dominant risk factor [1-2]
- HVPG ≥12 mmHg — threshold for variceal bleeding [13]
- Large variceal size and red wale marks on endoscopy — strongest endoscopic predictors [1-2][7]
- Child-Pugh class B or C — independent predictor of bleeding (OR 19–40) [14]
- Decompensated cirrhosis (ascites, encephalopathy, jaundice) [1]
- Active alcohol use — accelerates variceal progression [7]
- Non-compliance with beta-blocker prophylaxis
- Thrombocytopenia (<110 × 10⁹/L) — marker of clinically significant portal hypertension [10]
- H. pylori infection — independent predictor of variceal bleeding (OR 7.36) [14]
8. Differential Diagnosis
- Peptic ulcer bleeding — most common cause of UGIB overall; more often presents with melena alone; cirrhotic patients can have concurrent peptic ulcers (up to 38% of UGIB in cirrhotics is non-variceal) [8][15]
- Portal hypertensive gastropathy — more insidious, chronic blood loss, manifests as anemia rather than acute hemorrhage [2]
- Mallory-Weiss tear — linear tear at GEJ after retching/vomiting; usually self-limited [16]
- Gastric varices — especially GOV2/IGV1; require different endoscopic approach (cyanoacrylate) [3]
- Esophagitis/erosive disease — GERD-related; typically less severe bleeding
- Gastric/esophageal malignancy — more common in cirrhotic patients with HCC [8]
- Dieulafoy lesion or vascular ectasia — rare but can cause massive hemorrhage [16]
- Aortoenteric fistula — rare but catastrophic; consider in patients with prior aortic surgery
Distinguishing feature: Previous cirrhosis diagnosis or signs of chronic liver disease + red blood emesis + red NG aspirate has a 96–97% NPV for ruling out variceal bleeding when absent (UGIB Etiology Score). [5]
9. Past Medical History
- Prior variceal bleeding episodes (strongest predictor of rebleeding)
- Cirrhosis etiology and duration; prior decompensation events
- History of endoscopic band ligation or sclerotherapy
- Prior TIPS placement
- Hepatocellular carcinoma screening status
- Portal vein thrombosis
- Chronic kidney disease (affects resuscitation and drug dosing)
- Cardiac disease (affects transfusion thresholds and beta-blocker use)
10. Physical Exam
Vital signs
- Tachycardia, hypotension, orthostatic changes — assess hemodynamic stability first
- Tachypnea, oxygen desaturation
Focused exam
- Stigmata of chronic liver disease: spider angiomata, palmar erythema, gynecomastia, caput medusae, jaundice, temporal wasting
- Abdominal: hepatosplenomegaly, ascites (flank dullness 83% sensitive, shifting dullness 56% specific), caput medusae [10]
- Rectal: melena vs. hematochezia; stool color and consistency [6]
- Neurologic: asterixis, orientation, level of consciousness (West Haven Criteria for encephalopathy) [10]
- Extremities: peripheral edema, muscle wasting
11. Lab Studies
- CBC: hemoglobin (target ~7 g/dL for transfusion in absence of comorbidities), platelet count (thrombocytopenia suggests portal hypertension) [3][7]
- CMP: BUN/creatinine (hepatorenal syndrome), electrolytes, glucose
- LFTs: bilirubin, albumin, AST, ALT (for Child-Pugh and MELD scoring)
- Coagulation: PT/INR — note that INR does not reliably predict bleeding risk in cirrhosis [3]
- Type and crossmatch: prepare for transfusion
- Lactate: marker of tissue hypoperfusion/shock
- Blood cultures: if infection suspected as precipitant
- Ammonia: if encephalopathy present
- Fibrinogen: if DIC suspected
12. Imaging
- Abdominal ultrasound with Doppler: first-line to evaluate liver morphology, portal vein patency/flow, splenomegaly, ascites [2]
- Portal vein POCUS in the ED: portal vein diameter >13 mm, decreased flow velocity, and splenomegaly predict variceal etiology (SCoPE score AUC 0.843) [17]
- CT abdomen with contrast: evaluate for portal vein thrombosis, HCC, and vascular anatomy if TIPS or endovascular procedure is planned [3]
- Transient elastography (FibroScan): liver stiffness measurement for non-invasive assessment of portal hypertension in the outpatient setting; LSM <20 kPa + platelets >150K can rule out high-risk varices [10][18]
- Imaging is not needed to diagnose acute variceal bleeding — endoscopy is the gold standard
13. Special Tests
Scoring systems
Procedures
- Esophagogastroduodenoscopy (EGD): gold standard for diagnosis and treatment; perform within 12 hours of presentation [3][13]
- Hepatic venous pressure gradient (HVPG): gold standard for portal pressure measurement; CSPH defined as ≥10 mmHg; bleeding risk at ≥12 mmHg [10][13]
14. ECG
- Obtain ECG in all patients with acute GI bleeding to assess for:
- Tachycardia — most common finding; reflects hypovolemia
- ST changes/ischemia — demand ischemia from anemia and hypotension
- QTc prolongation — common in cirrhosis; relevant when using octreotide
- Arrhythmias — electrolyte derangements (hypokalemia, hypomagnesemia) from cirrhosis/diuretics
- ECG findings may alter transfusion threshold (target Hgb >7–8 g/dL in patients with coronary disease) [3]
15. Assessment
Esophageal varices represent a spectrum from asymptomatic (found on screening) to life-threatening hemorrhage. Severity stratification is critical:
- Compensated cirrhosis without varices: lowest risk; screen with EGD every 2–3 years [7][10]
- Small varices without red signs: moderate risk; EGD every 1–2 years; consider NSBB [7]
- Large varices or red wale marks: high risk (~15%/year bleeding rate); requires primary prophylaxis [1-2]
- Acute variceal hemorrhage: medical emergency; 6-week mortality 10–15%; highest mortality in Child-Pugh C patients [3]
- Post-bleeding: high rebleeding risk without secondary prophylaxis (~60% at 1 year without treatment)
Complications to anticipate: aspiration pneumonia (most common infection during admission for variceal bleeding), hepatorenal syndrome, hepatic encephalopathy, spontaneous bacterial peritonitis, and multiorgan failure. [3][8]
16. Treatment Plan
Acute variceal hemorrhage — initial stabilization
- Airway: intubate if altered mental status, massive hematemesis, or high aspiration risk [3][7]
- IV access: two large-bore IVs; avoid aggressive crystalloid resuscitation [7]
- Restrictive transfusion: target Hgb ~7 g/dL (higher if active coronary disease) [3]
- Start octreotide immediately: 50 mcg IV bolus → 25–50 mcg/hr infusion [3][7]
- Start IV ceftriaxone 1 g q24h [3]
- Urgent EGD within 12 hours; IV erythromycin 125–250 mg pre-endoscopy [3]
Endoscopic therapy
- Endoscopic variceal ligation (EVL) is the treatment of choice for esophageal varices [3][11]
- Repeat EVL every 2–4 weeks until variceal obliteration [3]
Refractory bleeding
- Balloon tamponade (Sengstaken-Blakemore or Minnesota tube) or self-expanding metal esophageal stent as temporizing bridge [3][12]
- Pre-emptive TIPS within 72 hours for high-risk patients (Child-Pugh B with active bleeding or Child-Pugh C 10–13) — improved 1-year survival (86% vs 61%) [10]
Secondary prophylaxis (post-bleed)
- Carvedilol (preferred, 6.25–12.5 mg daily) or propranolol + serial EVL every 2–4 weeks [10][21]
- TIPS for recurrent bleeding despite optimal medical/endoscopic therapy [10]
- Liver transplant evaluation for appropriate candidates [21]
Primary prophylaxis (no prior bleed)
- Large varices or high-risk stigmata: carvedilol 12.5 mg daily (preferred) or EVL [10-11]
- CSPH without varices: carvedilol reduces risk of decompensation (16% vs 27%) [10][18]
The following algorithm details the post-hemostasis management pathway including risk stratification for early TIPS:
17. Disposition
- ICU admission: all patients with acute variceal hemorrhage, hemodynamic instability, need for intubation, or active bleeding [3][7]
- Stepdown/floor admission: hemodynamically stable patients post-successful EVL, for monitoring of rebleeding and continuation of octreotide/antibiotics (2–5 days)
- Observation: not appropriate for acute variceal bleeding
- Discharge criteria: hemodynamically stable, no rebleeding for ≥24–48 hours, tolerating oral intake, beta-blocker initiated, outpatient follow-up arranged
Specialist consultation triggers
- GI/hepatology: all patients with suspected or confirmed variceal bleeding
- Interventional radiology: for TIPS consideration in refractory or high-risk bleeding [3]
- Transplant surgery: Child-Pugh C patients or MELD ≥15 [21]
- Critical care: hemodynamic instability, need for vasopressors, intubation
18. Follow Up / Return Precautions
Follow-up timing
- Repeat EGD in 2–4 weeks for serial EVL until variceal obliteration [3]
- Hepatology follow-up within 1–2 weeks of discharge
- Ongoing EGD surveillance: every 6–12 months after variceal obliteration, then per risk stratification [7]
- HCC screening with ultrasound ± AFP every 6 months [2]
Return precautions — instruct patients to seek immediate care for:
- Any hematemesis or bloody/black tarry stools
- Lightheadedness, dizziness, or fainting
- Increasing abdominal swelling
- Confusion or excessive drowsiness
- Fever or chills
Patient counseling
- Absolute alcohol cessation — single most impactful modifiable factor [10]
- Beta-blocker adherence — do not stop abruptly; report dizziness or bradycardia
- Avoid NSAIDs and aspirin unless specifically directed
- Expected recovery: rebleeding risk is highest in the first 6 weeks; with optimal prophylaxis (NSBB + EVL), rebleeding rates decrease significantly [11][21]
References
1. Band Ligation Versus No Intervention for Primary Prevention of Upper Gastrointestinal Bleeding in Adults With Cirrhosis and Oesophageal Varices. — Vadera S, Yong CWK, Gluud LL, Morgan MY. The Cochrane Database of Systematic Reviews. 2019.
2. Liver Cirrhosis. — Ginès P, Krag A, Abraldes JG, et al. Lancet. 2021.
3. AASLD Practice Guidance on Risk Stratification and Management of Portal Hypertension and Varices in Cirrhosis. — Kaplan DE, Ripoll C, Thiele M, et al. Hepatology. 2024.
4. Management of upper gastrointestinal hemorrhage related to portal hypertension. — Patrick S. Kamath, Louis M. Wong Kee Song Yamada's Textbook of Gastroenterology 7e. 2022.
5. Upper Gastrointestinal Bleeding Etiology Score for Predicting Variceal and Non-Variceal Bleeding. — Pongprasobchai S, Nimitvilai S, Chasawat J, Manatsathit S. World Journal of Gastroenterology. 2009.
6. Gastrointestinal Surgical Emergencies Textbook. — Ashley E. Aaron, Andrea Amabile, Ciro Andolfi, et al American College of Surgeons (2021). 2021.
7. The Role of Endoscopy in the Management of Variceal Hemorrhage. — Hwang JH, Shergill AK, Acosta RD, et al. Gastrointestinal Endoscopy. 2014.
8. Characteristics of Peptic Ulcer Bleeding in Cirrhotic Patients With Esophageal and Gastric Varices. — Lu Z, Sun X, Han J, et al. Scientific Reports. 2020.
9. Acute-on-Chronic Liver Failure. — Arroyo V, Moreau R, Jalan R. The New England Journal of Medicine. 2020.
10. Diagnosis and Management of Cirrhosis and Its Complications: A Review. — Tapper EB, Parikh ND. The Journal of the American Medical Association. 2023.
11. Comprehensive Approach to Esophageal Variceal Bleeding: From Prevention to Treatment. — Singh S, Chandan S, Vinayek R, et al. World Journal of Gastroenterology. 2024.
12. Review article: Upper gastrointestinal bleeding – review of current evidence and implications for management. — Shung DL, Laine L. Alimentary Pharmacology & Therapeutics. 2024.
13. Managing Liver Cirrhotic Complications: Overview of Esophageal and Gastric Varices. — Lesmana CRA, Raharjo M, Gani RA. Clinical and Molecular Hepatology. 2020.
14. Clinical Characteristics and Predictors of Esophagogastric Variceal Bleeding Among Patients With HCV-induced Liver Cirrhosis: An Observational Comparative Study. — El Sheref SEDM, Afify S, Berengy MS. PloS One. 2022.
15. Management of Variceal and Nonvariceal Upper Gastrointestinal Bleeding in Patients With Cirrhosis. — Cremers I, Ribeiro S. Therapeutic Advances in Gastroenterology. 2014.
16. Upper Gastrointestinal Bleeding Due to a Peptic Ulcer. — Laine L. The New England Journal of Medicine. 2016.
17. A Portal Into Hemodynamics: Utility of Portal Vein Ultrasound in Predicting Variceal Etiology of Upper Gastrointestinal Hemorrhage in the Emergency Department. — Naik S, Ravindra P, Chaudhuri S, et al. Internal and Emergency Medicine. 2025.
18. Noninvasive Assessment of Liver Fibrosis. — Castera L, Rinella ME, Tsochatzis EA. The New England Journal of Medicine. 2025.
19. Platelet Count, Spleen Length, and Platelet Count-to-Spleen Length Ratio for the Diagnosis of Oesophageal Varices in People With Chronic Liver Disease or Portal Vein Thrombosis. — Colli A, Gana JC, Yap J, et al. The Cochrane Database of Systematic Reviews. 2017.
20. Upper Gastrointestinal Bleeding in Adults: Evaluation and Management. — Wilkins T, Wheeler B, Carpenter M. American Family Physician. 2020.
21. Treatment of Oesophageal Varices in Liver Cirrhosis. — Sauerbruch T, Wong F. Digestion. 2018.
22. Management of upper gastrointestinal hemorrhage related to portal hypertension. — Patrick S. Kamath, Louis‐Michel Wong Kee Song Yamada's Atlas of Gastroenterology. 2022.